降糖消脂颗粒对2型糖尿病气阴两虚、痰瘀互阻患者的影响  

Effects of Jiangtang Xiaozhi Granules on Vascular Endothelial Function in Type 2 Diabetes Patients with Qi-Yin Deficiency and Phlegm-Stasis Inter-obstruction Syndrome

作　　者：陈筑红[1] 张广德[1] 魏子孝[1] 余欢欢[1] CHEN Zhu-hong, ZHANG Guang-de, WEI Zi-xiao, and YU Huan-huan(Department of Endocrinology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing （1000911）)

机构地区：[1]中国中医科学院西苑医院内分泌科,北京100091

出　　处：《中国中西医结合杂志》2018年第5期544-548,共5页Chinese Journal of Integrated Traditional and Western Medicine

基　　金：中国中医科学院名医名家传承项目(No.CM20141003);中国中医科学院西苑医院苗圃课题[No.XYKY-MP(2013)-10]

摘　　要：目的评价降糖消脂颗粒治疗2型糖尿病(T2DM)气阴两虚、痰瘀互阻证患者的疗效及安全性,并观察其对内皮细胞因子的影响。方法采用前瞻性随机、平行、对照试验方法,应用随机数字表法将60例气阴两虚、痰瘀互阻证患者分为降糖消脂颗粒组(试验组29例)和二甲双胍组(对照组31例)。入组后两组患者均维持原基础治疗及生活方式不变,试验组加用降糖消脂颗粒口服,每次1袋,每天2次;对照组加用二甲双胍缓释片口服,每次0.5g,每天1次,均连续服用12周。记录治疗前后两组患者体重、腰围、体重指数(BMI)、中医症状评分;检测血糖[空腹血浆血糖(FBG)、餐后2h血糖(PBG)、糖化血红蛋白(HbA1c)]、空腹胰岛素水平(FINS)、血脂(TC、TG、HDL-C、LDL-C)、超敏C反应蛋白(hs-CRP)、一氧化氮(NO)、内皮素(ET)水平,计算稳态模型胰岛素抵抗指数(HOMA-IR);记录肝、肾功能及不良事件。结果与本组治疗前比较,试验组治疗后体重、腰围、TC、LDL-C、ET降低(P<0.05);对照组BMI、ET下降(P<0.05);两组患者中医症状积分降低(P<0.01),且试验组改善程度优于对照组(P<0.05)。病程<12个月患者中,与治疗前比较,两组患者治疗后HbA1c、FBG下降(P<0.05),且试验组较对照组下降更明显(P<0.05)。观察过程中两组均未发生严重不良事件。结论降糖消脂颗粒具有降低T2DM气阴两虚、痰瘀互阻证患者FBG、HBA1c、TC、LDL-C及改善内皮细胞因子的作用,对病程<12个月患者疗效更优,与二甲双胍缓释片相当,无严重不良反应。Objective To evaluate the efficacy and safety of Jiangtang Xiaozhi Granules（ J TXZG）in treating type 2 diabetes mellitus（ T2 DM） patients with qi-yin deficiency and phlegm-stasis inter-obstruction syndrome（ QYDPSIOS）,to observe its effect on endothelial cell factors. Methods In a randomized, parallel control, and prospective study,6 0 T2 DM patients with QYDPSIOS were randomly assigned to two groups, the Extended-release metformin group（31 cases,as the control） and the JTXZG group（29 cases）. All patients maintained their basic therapies and lifestyle as previous after recruitment.Patients in the J TXZG group took JTXZG,one bag each time,twice per day,while those in the control group took Extended-release metformin,0. 5 g each time,once per day,the course lasted 12 weeks.The body weight（ BW）,the waistline（ W）, body mass index（ BMI） and scoring of Chinese medicine（CM） symptoms were observed,Levels of fasting blood glucose（ FBG）,2 h postprandial blood glucose（PBG）,glycated hemoglobin（ H b A1 c）,fasting in su lin（ FINS）,TC,TG,H DL-C,LDL-C,hypersen sitiv C-reactive protein（ hs-CRP）,Nitric oxide（ NO）,Endothelin（ ET） were detected,the steady-state model insulin resistance index（ HOMA-IR） was calculated. The safety indices such as liver and renal functions and adverse reactions were also monitored. Results Com pared with before treatment,BW,W,TC,LDL-C and ET decreased after treatment in JTXZG group（P〈0.05）,BMI and ET decreased after treatment in the control group（P〈0.05）. The scores of CM symptoms were improved after treatment in both groups（P〈0.01）. In the patients whose courses were less than 12-month,compared with before treatment,the HbAlc and FBG were decreased in both groups（P〈0.05）, the JTXZG group decreased more than control group（P0.05）. No severe adverse event occurred in either group during the whole therapeutic course.Conclusions JTXZG could effectively decrease FBG,H BA 1 c,TC and LDL-C,and improve endothelial cel

关 键 词：降糖消脂颗粒 气阴两虚 痰瘀内阻 2型糖尿病 内皮细胞因子 

分 类 号：R259[医药卫生—中西医结合]